The average one-year price target for Wave Life Sciences (NasdaqGM:WVE) has been revised to $32.70 / share. This is an increase of 60.82% from the prior estimate of $20.34 dated December 3, 2025. The ...

As of Friday, December 19, Cassava Sciences, Inc.’s SAVA share price has dipped by 17.37%, which has investors questioning if this is right time to buy.

Canaccord analyst Kyle Mikson raised the firm’s price target on Caris Life Sciences (CAI) to $30 from $28 and keeps a Hold rating on the shares.

180 Life Sciences (ATNF) announced that it has entered into a securities purchase agreement with several institutional investors to sell 1,200,000 shares of common stock in a registered direct ...

Barclays raised the firm’s price target on Integral Ad Science (IAS) to $14 from $13 and keeps an Equal Weight rating on the shares. With software “back in favor again,” valuation levels have now ...

BTIG analyst Mark Massaro lowered the firm’s price target on Exact Sciences (EXAS) to $65 from $82 and keeps a Buy rating on the shares. The company delivered a Q3 revenue miss and large guide-down, ...

He now feels Wave stock rates an outperform (buy, in other words), one full notch up from his previous sector perform (hold).

Clean Science Share: compare Clean Science with up to two competing stocks only on Moneycontrol. Use our stock comparison tool to check price, market cap, returns & more ...

Caris Life Sciences (NASDAQ:CAI) is scheduled to make its trading debut on Wednesday on the Nasdaq after the Irving, Texas-based cancer diagnostics company priced its initial public offering at $21.00 ...

CAMBRIDGE, Mass., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform ...